DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "hold" rating on the stock.

Several other analysts have also recently weighed in on DBVT. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright boosted their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT traded up $0.03 during trading hours on Tuesday, hitting $0.82. The company's stock had a trading volume of 580,309 shares, compared to its average volume of 238,218. The business has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $0.94. The stock has a market cap of $79.12 million, a price-to-earnings ratio of -0.96 and a beta of 0.67. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.17.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same period in the previous year, the firm posted ($0.26) earnings per share. On average, equities research analysts forecast that DBV Technologies will post -1.43 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,568,909 shares of the company's stock after acquiring an additional 327,345 shares during the period. DBV Technologies comprises approximately 0.2% of Yiheng Capital Management L.P.'s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.